ADAR1 Capital Management LLC Purchases Shares of 204,348 Alpha Cognition, Inc. (NASDAQ:ACOG)

ADAR1 Capital Management LLC acquired a new stake in shares of Alpha Cognition, Inc. (NASDAQ:ACOG) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 204,348 shares of the company’s stock, valued at approximately $1,204,000. ADAR1 Capital Management LLC owned about 1.28% of Alpha Cognition as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Aristides Capital LLC bought a new stake in shares of Alpha Cognition in the 4th quarter worth about $1,178,000. National Bank of Canada FI bought a new stake in Alpha Cognition in the 4th quarter valued at approximately $69,000. Finally, Rosalind Advisors Inc. bought a new stake in Alpha Cognition during the 4th quarter worth about $1,489,000.

Alpha Cognition Stock Down 3.2 %

ACOG stock opened at $4.83 on Monday. The firm has a 50 day moving average of $5.73. The company has a market capitalization of $77.38 million, a price-to-earnings ratio of -1.89 and a beta of 2.50. Alpha Cognition, Inc. has a twelve month low of $4.28 and a twelve month high of $7.00.

Alpha Cognition (NASDAQ:ACOG) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.03).

Wall Street Analyst Weigh In

Several research firms have recently commented on ACOG. Raymond James raised Alpha Cognition to a “moderate buy” rating in a report on Tuesday, March 25th. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Alpha Cognition in a report on Monday, March 31st.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.